Recent Merger and Acquisition Activity in Sealants, Glues and Hemostats

Growth in sealants, glues, and hemostats markets has been strong enough for long enough to have attracted a lot of players. With growth slowing as the untapped potential is reducing more rapidly, consolidation has now appeared in the natural order of things.

Recent Merger and Acquisition Activity in Sealants, Glues and Hemostats

Original Company/ ProductAcquiring or Collaborating CompanyDate of Acquisition/Collaboration DealFinancial Details (where revealed)
Bristol-Myers Squibb/ Recothrom¨ Thrombin topical hemostatThe Medicines Company2012/2014$105 million collaboration fee
Cohera Medical/TissuGlu¨Collaboration with B. Braun Surgical S.A. to distribute in Germany, Spain and Portugal.Jan. 2015B. Braun Surgical S.A. will exclusively market and sell TissuGlu in the territories of Germany, Spain and Portugal through its existing Closure Technologies commercial teams.
Profibrix/ FibroCapsThe Medicines Company2013$90 million, with $140 million contingent upon milestones
Medafor/Arista¨ AH Absorbable Hemostatic ParticlesCR Bard (Bard Davol)2013$200 million upfront payment
Tenaxis Medical, with ArterX (among other products)The Medicines Company2014$58 million in upfront payments
The Medicines Company/ PreveLeakª (formerly known as ArterX), Raplixaª(formerly known as FibroCaps) fibrin sealant, Recothrom¨ Thrombin topical (Recombinant) sealantMallinckrodt plc2016The entire deal has a potential value of $410 million.
Xcede Technologies, Inc./Resorbable Hemostatic PatchCollaboration with Cook BiotechJan-16Signed three collaboration agreements with Cook Biotech, including a Development Agreement, a License Agreement and a Supply Agreement to complete development, seek regulatory clearance and produce XcedeÕs resorbable hemostatic patch.

Source: MedMarket Diligence, LLC; Report #S290.

Medtech old school: Ablation technologies

Compared to the use of cellular based technologies, gene editing, nanotech, and even more promising technologies ahead, the technology of ablation — the use of simple energy at various wavelengths, at various temperatures, intensities, methods desigend to be effective, accurate, and precise —  is not as sexy, but these technologies really are medtech old school.

Indeed, ablation technologies may not be able to compete effectively against cell therapy, gene therapy, or other advanced medical technologies, especially where “cure” is a reality, but they really do stand at the forefront of surgery today (and in some sense as the likely peak of device technologies). They are not concepts or potential technologies, but are treating myriad diseases today, offering better outcomes and improving quality of lives and saving lives.

Growth rates in sales of devices, equipment, and supplies in most ablation types are at least respectable in an era of cost containment, while other ablation modalities are strong enough in tapping unmet patient demand that they are investment-attractive. Just as these technologies have emerged and developed alongside other MIS technologies, they will continue to track surgeries (or interventions, sorry cardio guys) and be there until surgery, interventional medicine, or whatever its moniker, is made obsolete.

See the Smithers Apex report, “The Future of Ablation Products to 2020,” described at link.

Screen Shot 2016-07-21 at 3.42.15 PM

Source: Smithers Apex

Medtech fundings for July 2016

Medtech fundings for July 2016 stand at $471 million, led by the $183 million IPO of Bioventus, followed by the $32 million funding of Endotronix and the $30 million funding of Senseonics.

Below are the top fundings for the month thus far. Check back before month end to see updates.

Screen Shot 2016-07-21 at 9.39.02 AM

For a complete list of fundings in July 2016, see link.

Sealants, Glues, Hemostats development, markets globally in new report

Worldwide Markets for Medical and Surgical Sealants, Glues, and Hemostats, 2015-2022.” Report #S290.

sealants graphic better

Fibrin and Other Sealants — Impacts of Emerging Market Growth

Screen Shot 2016-07-17 at 6.19.22 PM

Source: MedMarket Diligence, LLC; Report #S290.

Hemostats doing relatively well to 2022

Sales of hemostats will outpace products for sealing or adhesion of tissue, especially in Asia-Pacific.

Screen Shot 2016-07-13 at 11.28.58 PM

Source: MedMarket Diligence, LLC; Report #S290.

Growth of Surgical Sealants and Glues in Asia-Pacific

Screen Shot 2016-07-13 at 10.19.17 AM

Source: MedMarket Diligence, LLC; Report #S290.

Cardiovascular Surgical Procedures, Technologies Trended Globally to 2022

cardiovascular procedures

Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022. See Report #C500.

Publishing July 2016

This report covers surgical and interventional therapeutic procedures commonly used in the management of acute and chronic conditions affecting myocardium and vascular system. The latter include ischemic heart disease (and its life threatening manifestations like AMI, cardiogenic shock, etc.); heart failure; structural heart disorders (valvular abnormalities and congenital heart defects); peripheral artery disease (and limb and life threatening critical limb ischemia); aortic disorders (AAA, TAA and aortic dissections); acute and chronic venous conditions (such as deep venous thrombosis, pulmonary embolism and chronic venous insufficiency); neurovascular pathologies associated with high risk of hemorrhagic and ischemic stroke (such as cerebral aneurysms and AVMs, and high-grade carotid/intracranial stenosis); and cardiac rhythm disorders (requiring correction with implantable pulse generators/IPG or arrhythmia ablation).

The report offers current assessment and projected procedural dynamics (2015 to 2022) for primary market geographies (e.g., United States, Largest Western European Countries, and Major Asian States) as well as the rest-of-the-world.

See the complete table of contents at Report C500.

 

 

Abbott’s fully-absorbing stent gets FDA nod

AbsorbOUS-heroAbbott’s resorbable coronary stent, Absorb, gained FDA regulatory approval today, the first for a fully-dissolving coronary stent. Designed to be fully resorbed by the body within three years of implantation, the device is intended to achieve the endpoint of a more natural vasculature than can be achieved with metal stents.


In July 2016, MedMarket Diligence is publishing, “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022”, Report #C500.

Fibrin, Thrombin, Collagen and Gelatin-Based Sealants, 2016 & 2022

fibrin2016

Source: MedMarket Diligence, LLC; Report #S290 (July 2016).

fibrin2022

Source: MedMarket Diligence, LLC; Report #S290 (July 2016).

collagen2016

Source: MedMarket Diligence, LLC; Report #S290 (July 2016).

collagen2022

Source: MedMarket Diligence, LLC; Report #S290 (July 2016).